VACCINES AND HEPATITIS B

Alderman, 1998, Is prevaccination screening for hepatitis B among sexually active adolescents cost-effective?, Clin Infect Dis, 26, 1450, 10.1086/516346 Alimonos, 1998, Prediction of response to hepatitis B vaccine in health care workers: Whose titers of antibody to hepatitis B surface antigen should be determined after a three-dose series, and what are the implications in terms of cost-effectiveness?, Clin Infect Dis, 26, 566, 10.1086/514575 Alper, 1989, Genetic prediction of nonresponse to hepatitis B vaccine, N Engl J Med, 321, 708, 10.1056/NEJM198909143211103 Belloni, 1998, Immunogenicity of hepatitis B vaccine in term and preterm infants, Acta Paediatr, 87, 336, 10.1111/j.1651-2227.1998.tb01448.x Bulkow, 1998, Increases in levels of antibody to hepatitis B surface antigen in an immunized population, Clin Infect Dis, 26, 933, 10.1086/513939 Chang, 1997, Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children, N Engl J Med, 336, 1855, 10.1056/NEJM199706263362602 Chen, 1996, Seroepidemiology of hepatitis B virus infection in children. Ten years of mass vaccination in Taiwan, JAMA, 276, 906, 10.1001/jama.1996.03540110060032 Chow, 1998, Development of Th1 and Th2 populations and the nature of immune responses to hepatitis B virus DNA vaccines can be modulated by codelivery of various cytokine genes, J Immunol, 160, 1320 Clemens, 1997, Booster immunization of low- and non-responders after a standard three dose hepatitis B vaccine schedule—results of a post-marketing surveillance, Vaccine, 15, 349, 10.1016/S0264-410X(96)00205-8 Dobson, 1995, Assessment of a universal, school-based hepatitis B vaccination program, JAMA, 274, 1209, 10.1001/jama.1995.03530150033030 Fomsgaard, 1998, Improved humoral and cellular immune responses against the gp120 V3 loop of HIV-1 following genetic immunization with a chimeric DNA vaccine encoding the V3 inserted into the hepatitis B surface antigen, Scand J Immunol, 47, 289, 10.1046/j.1365-3083.1998.00323.x Geissler, 1997, Cellular and humoral immune response to hepatitis B virus structural proteins in mice after DNA-based immunization, Gastroenterology, 112, 1307, 10.1016/S0016-5085(97)70145-8 Goldwater, 1997, Randomized, comparative trial of 20 μg versus 40 μg Engerix B vaccine in hepatitis vaccine non-responders, Vaccine, 15, 353, 10.1016/S0264-410X(96)00202-2 Gramzinski, 1998, Immune response to a hepatitis B DNA vaccine in Aotus monkeys: A comparison of vaccine formulation, route and method of administration, Molec Med, 4, 109, 10.1007/BF03401734 Hadler, 1986, Long-term immunogenicity and efficacy of hepatitis B vaccine in homosexual men, N Engl J Med, 315, 209, 10.1056/NEJM198607243150401 1991, Hepatitis B virus: A comprehensive strategy for eliminating transmission in the United States through universal childhood vaccination. Recommendations of the Immunization Practices Advisory Committee (ACIP), MMWR, 40, 1 Keyserling, 1994, Antibody responses of healthy infants to a recombinant hepatitis B vaccine administered at 2, 4, and 12 or 15 months of age, J Pediatr, 125, 67, 10.1016/S0022-3476(94)70123-7 Knishern, 1994, Characterization and evaluation of a recombinant hepatitis B vaccine expressed in yeast defective for N-linked hyperglycosylation, Vaccine, 12, 1021, 10.1016/0264-410X(94)90339-5 Lemon, 1997, Vaccines to prevent viral hepatitis, N Engl J Med, 336, 196, 10.1056/NEJM199701163360307 LeRoux-Roels, 1996, Safety and immunogenicity of a combined hepatitis A and B vaccine in young healthy adults, Scand J Gastroenterol, 31, 1027, 10.3109/00365529609003124 Margolis, 1993, Host factors related to poor immunogenicity of hepatitis B vaccine in adults. Another reason to immunize early, JAMA, 270, 2971, 10.1001/jama.1993.03510240083038 Margolis, 1995, Prevention of hepatitis B virus transmission by immunization. An economic analysis of current recommendations, JAMA, 274, 1201, 10.1001/jama.1995.03530150025029 Marsano, 1998, A two-dose hepatitis B vaccine regimen: Proof of priming and memory responses in young adults, Vaccine, 16, 624, 10.1016/S0264-410X(97)00233-8 Ogata, 1997, Infectivity and pathogenicity in chimpanzees of a surface gene mutant of hepatitis B virus that emerged in a vaccinated infant, J Infect Dis, 175, 511, 10.1093/infdis/175.3.511 Papaevangelou, 1995, Evaluation of a combined tetravalent diphtheria, tetanus, whole-cell pertussis and hepatitis B candidate vaccine administered to healthy infants according to a three-dose vaccination schedule, Vaccine, 13, 175, 10.1016/0264-410X(95)93132-S Pillot, 1995, Weak immunogenicity of the preS2 sequence and lack of circumventing effect on the unresponsiveness to the hepatitis B virus vaccine, Vaccine, 13, 289, 10.1016/0264-410X(95)93316-2 Poovorawan, 1989, Protective efficacy of a recombinant DNA hepatitis B vaccine in neonates of HBe antigen-positive mothers, JAMA, 261, 3278, 10.1001/jama.1989.03420220092033 Prince, 1997, Successful nucleic acid based immunization of newborn chimpanzees against hepatitis B virus, Vaccine, 15, 916, 10.1016/S0264-410X(96)00248-4 Rajadhyaskha, 1995, Delineation of the minimal hepatitis B surface antigen-specific B- and T-cell epitope contained within an anti-idiotype-derived pentadecapeptide, Proceedings of the National Academy of Science USA, 92, 1575, 10.1073/pnas.92.5.1575 Schaffner, 1993, Hepatitis B immunization strategies: Expanding the target, Ann Intern Med, 118, 308, 10.7326/0003-4819-118-4-199302150-00011 Schodel, 1994, Hybrid hepatitis B virus core-pre-S proteins synthesized in avirulent Salmonella typhimurium and Salmonella typhi for oral vaccination, Infect Immun, 62, 1669, 10.1128/IAI.62.5.1669-1676.1994 Shouval, 1995, Transplantation of hepatitis B immune lymphocytes as means for adoptive transfer of immunity to hepatitis B virus, J Hepatology, 23, 98, 10.1016/0168-8278(95)80317-3 Silva, 1998, Hepatitis B virus DNA in persons with isolated antibody to hepatitis B core antigen who subsequently received hepatitis B vaccine, Clin Infect Dis, 26, 898, 10.1086/513918 Szmuness, 1980, Hepatitis B vaccine: Demonstration of efficacy in a controlled clinical trial in a high-risk population in the United States, N Engl J Med, 303, 833, 10.1056/NEJM198010093031501 Townsend, 1997, Characterization of CD8+ cytotoxic T-lymphocyte responses after genetic immunization with retrovirus vectors expressing different forms of the hepatitis B virus core and e antigens, J Virology, 71, 3363, 10.1128/JVI.71.5.3365-3374.1997 Traquina, 1996, MF59 adjuvant enhances the antibody response to recombinant hepatitis B surface antigen vaccine in primates, J Infect Dis, 174, 1168, 10.1093/infdis/174.6.1168 Treadwell, 1993, Immunogenicity of two recombinant hepatitis B vaccines in older individuals, Am J Med, 95, 584, 10.1016/0002-9343(93)90353-Q Waters, 1992, Loss of the common “A” determinant of hepatitis B surface antigen by a vaccine-induced escape mutant, J Clin Invest, 90, 2543, 10.1172/JCI116148 West, 1994, Persistence of immunologic memory for twelve years in children given hepatitis B vaccine in infancy, Ped Infect Dis J, 13, 745, 10.1097/00006454-199408000-00015 Whittle, 1995, Long-term efficacy of continuing hepatitis B vaccination in infancy in two Gambian villages, Lancet, 345, 1089, 10.1016/S0140-6736(95)90822-6